Skip to content

Addiction: all studies

Page 550 of 857: studies 5,491 to 5,500 of 8,563, newest first. Back to the addiction overview

Research

(R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism

The International Journal of Neuropsychopharmacology July 16, 2019 Yukio Ago, Wataru Tanabe, Momoko Higuchi et al. 91 citations

BACKGROUND: Although recent studies provide insight into the molecular mechanisms of the effects of ketamine, the antidepressant mechanism of ketamine enantiomers and their metabolites is not fully understood. In view of the involvement of mechanisms other than the N-methyl-D-aspartate receptor in ketamine's action, we investigated the effects of (R)-ketamine, (S)-ketamine, (R)-norketamine...

Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice

Psychopharmacology July 15, 2019 Aboagyewaah Oppong‐Damoah, Kristen Curry, Bruce E. Blough et al.

Approximately 20 million adults in the USA have an alcohol use disorder (AUD). There are clinical and preclinical data suggesting that psychedelics may have benefits for AUD. To investigate the effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on the behavioral effects of ethanol. The effects of DOI were examined using ethanol-induced place conditioning (1.8 g/kg...

Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.

Journal of Psychopharmacology July 11, 2019 Leor Roseman, Eline Haijen, Kelvin Idialu-Ikato et al. 415 citations

Background: Psychedelic therapy is gaining recognition and the nature of the psychedelic experience itself has been found to mediate subsequent long-term psychological changes. Much emphasis has been placed on the occurrence of mystical-type experiences in determining long-term responses to psychedelics yet here we demonstrate the importance of another component, namely: emotional breakthrough....

DOI: 10.1177/0269881119855974 (opens in new tab) Psychedelics Hallucinogens Entheogens Mind-altering substances +16

Xamanismo e enteogenia ameríndia: A ayahuasca e outras “plantas de poder” em contextos indigenistas e vegetalistas amazônicos

Aceno - Revista de Antropologia do Centro-Oeste July 7, 2019 Wagner Lins Lira 1 citation

Este ensaio tem a finalidade de refletir sobre fenômenos culturais e etnológicos condizentes aos saberes e perspectivas ameríndios acerca do uso de substâncias enteogénicas, tangencialmente, da bebida ayahuasca, cujas matrizes repousam em contextos indigenistas, desde tempos pré-colombianos. Igualmente, visamos discorrer sobre o curandeirismo vegetalista em áreas rurais e urbanas fenômeno, onde...

Role of a VGF/BDNF/TrkB Autoregulatory Feedback Loop in Rapid-Acting Antidepressant Efficacy.

Journal of Molecular Neuroscience July 2019 Cheng Jiang, Wei-Jye Lin, Stephen R Salton

Members of the neurotrophin family and in particular brain-derived neurotrophic factor (BDNF) regulate the response to rapid- and slow-acting chemical antidepressants and voluntary exercise. Recent work suggests that rapid-acting antidepressants that modulate N-methyl-D-aspartate receptor (NMDA-R) signaling (e.g., ketamine and GLYX-13) require expression of VGF (non-acronymic), the...

EEG predictors of dreaming outside of REM sleep.

Psychophysiology July 1, 2019 Jing Zhang, Erin J. Wamsley

The stream of human consciousness persists during sleep, albeit in altered form. Disconnected from external input, the mind and brain remain active, at times creating the bizarre sequences of thought and imagery that comprise "dreaming." Yet despite substantial effort toward understanding this unique state of consciousness, no reliable neurophysiological indicator of dreaming has been...

DOI: 10.1111/psyp.13368 (opens in new tab) Full text (opens in new tab) EEG Analysis/statistical methods Cognition FMRI +3

Impact of Pharmacological Manipulation of the κ-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice.

Journal of Pharmacology and Experimental Therapeutics July 1, 2019 Eduardo R Butelman, Bryan D McElroy, Thomas E Prisinzano et al.

The kappa (κ) opioid receptor/dynorphin system modulates depression-like states and anhedonia, as well adaptations to stress and exposure to drugs of abuse. Several relatively short-acting small molecule κ-receptor antagonists have been synthesized, and their behavioral profile has been examined under some conditions. The hypothesis of this study is that pharmacological manipulations of the...

Mystical techniques, mental processes, and states of consciousness in Abraham Abulafia’s Kabbalah: A reassessment

Archive for the Psychology of Religion July 1, 2019 Vadim Putzu

This article reevaluates the mystical techniques and experiences peculiar to Abraham Abulafia’s Kabbalah and attempts to offer an alternative approach to their dominant understanding, which largely depends on Moshe Idel’s work. Current scholars of Jewish mysticism have a habit of highlighting the “unique character” of Abulafia’s mystical practices while asserting that they cannot be compared...

(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.

British Journal of Pharmacology July 1, 2019 Panos Zanos, Jaclyn N. Highland, Xin Liu et al.

(R)-Ketamine (arketamine) may have utility as a rapidly acting antidepressant. While (R)-ketamine has lower potency than (R,S)-ketamine to inhibit NMDA receptors in vitro, the extent to which (R)-ketamine shares the NMDA receptor-mediated adverse effects of (R,S)-ketamine in vivo has not been fully characterised. Furthermore, (R)-ketamine is metabolised to (2R,6R)-hydroxynorketamine (HNK),...

Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.

Pharmacology & Therapeutics July 1, 2019 T. H. Pham, Alain M. Gardier 190 citations

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays a fast antidepressant activity in treatment-resistant depression and in rodent models of anxiety/depression. A large body of evidence concerning the cellular and molecular mechanisms underlying its fast antidepressant-like activity comes from animal studies. Although structural remodeling of...